Join the club for FREE to access the whole archive and other member benefits.

Nano-enhanced tobramycin treats severe lung infections with only 2 doses

Antibiotic's efficacy improved by 100,000 times in treating cystic fibrosis - currently in preclinical stage


Key points from article :

Nanotechnology can improve the effectiveness of the cystic fibrosis (CF) antibiotic Tobramycin, by up to 100,000-fold.

Treats chronic Pseudomonas aeruginosa lung infections in severe CF—eradicating the infection in as little as two doses.

Tobramycin works by inhibiting the synthesis of bacteria and causing cell membrane damage.

Enhanced the Tobramycin with a biometric, nanostructured, lipid liquid crystal nanoparticle (LCNP)-based material.

"This could be a real game-changer for people living with CF," - Chelsea Thorn, co-author of the study.

Testing on a new lung infection model to showcase its unique ability to penetrate the dense surface of the bacteria and kill the infection.

"Our technology improves the performance of Tobramycin without increasing the toxicity of the drug," - Nicky Thomas, corresponding study author.

Currently entering pre-clinical trials and hopes to be on the market in the next five years.

Study by the University of South Australia published in the journal Small.

Mentioned in this article:

Click on resource name for more details.

Chelsea Thorn

Pharmacist, PhD student at the University of South Australia

Nicky Thomas

Senior Research Fellow at the School of Pharmacy & Medical Sciences, University of South Australia


Nanotechnology scientific journal

University of South Australia (UniSA)

Public Research university.

Topics mentioned on this page:
Nanomedicines, Respiratory Disease